346AAASLD ABSTRACTSHEPATOLOGY, October, 2013
based on practice guidelines helps in improving the way wecare for our patients with cirrhosis.
Disclosures:
The following people have nothing to disclose: Deepak N. Amarapurkar, MadhuriR. Chandnani, Mrudul V. Dharod, Rajiv Baijal, Praveen Kumar, Nikhil Patel, Pra-ful Kamani, Sanjeev Issar, Mayank Jain, Sonali Gautam, Apurva Shah, NimishShah, Deepak T. Gupta, Sandeep S. Kulkarni, Soham S. Doshi
279
Development of an algorithm based on ICD-9 codes toidentify patients with decompensated cirrhosis
Wadih Chacra1, David Rabin1, James J. Yang2, Stuart C. Gordon1;1Gastroenterology and hepatology, Henry Ford Hospital, Detroit,MI; 2Public health sciences, Henry Ford Health system, Detroit, MI
Purpose: We sought to develop an algorithm to identify viralhepatitis patients with decompensated cirrhosis based on ICD-9 and CPT diagnosis and procedure codes as a useful tool tofacilitate clinical research. Methods: A random sample of 283patients with chronic hepatitis B (CHB) or C (CHC) was identi-fied from the CHeCS (Chronic Hepatitis Cohort Study) data-base that includes patients from four large US based healthsystems. A chart review was conducted independently by twogastroenterology fellows and each patient was classified intoone of three categories: non-cirrhotic, compensated cirrhotic, ordecompensated cirrhotic. Any disagreement on the classifica-tion triggered a review by a clinical hepatologist for final adju-dication. Separately, we electronically collected diagnosis andprocedure codes typically associated with cirrhosis and decom-pensated cirrhosis from the patients’ medical records. We thendeveloped a logistic regression model for decompensated cir-rhosis based on the presence or absence of these codes in thepatient’s medical record. Forward, backward and stepwisemodel selection were used to determine the final model. Results:There were 255 CHC patients, 23 CHB patients, and 5CHB/CHC coinfected patients in the sample. The 41 diagnosisand procedure codes were clustered into ten binary variablesbased on the presence or absence of the following conditions:C1 liver transplant, C2 hepatocellular carcinoma, C3 liver fail-ure, C4 hepatic encephalopathy, C5 portal hypertension, C6bleeding esophageal varices, C7 other gastrointestinal hemor-rhage, C8 ascites, C9 other sequelae of chronic liver disease,and C10 cirrhosis. The final multivariable model retained C1,C2, C6 and C8 as independent predictors of decompensatedcirrhosis. Area under the receiver operating curve (AUC) was0.90. For practical application, we also developed a simplifiedmodel using a single predictor variable Z. WhenZ1=C1+C2+C6+C8, the AUC was 0.89 and the positive pre-dictive value (PPV) of Z1 ≥2 for decompensated cirrhosis was94%. When C1 and C2 were excluded from the model, theAUC for C6 and C8 alone was 0.75. A third model whereZ2=C4+C6+C8+C10 had an AUC of 0.83 and a PPV of 87%for Z2 ≥2. Conclusion: Algorithms based on ICD-9 codesrelated to bleeding esophageal varices and ascites were asso-ciated with a high likelihood of identifying CHB and CHCpatients with decompensated cirrhosis. This model could con-stitute a useful tool for epidemiological research and could alsobe used as a quality improvement measure to electronicallyprompt timely specialty referrals and monitor evidence basedcare of this patient population.
Disclosures:
Stuart C. Gordon - Advisory Committees or Review Panels: Tibotec; Consulting:Merck, CVS Caremark, Gilead Sciences, BMS; Grant/Research Support:Roche/Genentech, Merck, Vertex Pharmaceuticals, Gilead Sciences, BMS,Abbott, Intercept Pharmaceuticals, Exalenz Sciences, Inc.
The following people have nothing to disclose: Wadih Chacra, David Rabin,James J. Yang
280
MiR-223 deficiency prevents Fas-induced liver injurythrough activation of IGFR1
Ximena V. Qadir, Chang Han, Tong Wu; Pathology and LaboratoryMedicine, Tulane University School of Medicine, New Orleans, LA
MicroRNAs (miRNAs) are a class of small non-coding RNA mol-ecules that regulate the expression of target genes at post-tran-scriptional level. MiR-223 has been shown to play an importantrole in hematopoietic and immune cells; it has also been impli-cated in non-hematopoietic and non-immune cells. In the liver,the expression of miR-223 is increased during ischemic andreperfusion injury (Dig Dis Sci. 2009, 54:2362-6), while miR-223 is commonly repressed in hepatocellular carcinoma (Gas-troenterology 2008, 135:257-69). However, to date, little isknown about the biological function and mechanisms of miR-223 in liver biology and liver diseases. The current study wasdesigned to study the role of miR-233 in Fas-induced hepato-cyte apoptosis and liver injury. Wild-type (WT) and miR-223knockout (KO) mice were treated with the anti-Fas antibody Jo2(0.5μg/g of body weight) via i.p. injection to determine therate of animal survival and the extent of liver injury. WhereasWT mice died 4-6 hours after Jo2 injection (n=6), all of the miR-223 KO mice (n=6) survived (up to 72 hours after Jo2 injec-tion). In comparison to WT mice, the miR-223 KO mice showedresistance to Fas-induced liver injury, as indicated by less tissuedamage under histopathological examination, fewer apoptotichepatocytes under caspase-3 immunostaining, and decreasedserum ALT and AST levels. miR-223 KO livers show decreasedcaspase-3, -8 and -9 activities and decreased PARP cleavagecompared to wild type livers (p<0.05). Additionally, the miR-223 KO livers expressed higher level of insulin growth factorreceptor 1 (IGFR1), a predicted miR-223 downstream target(miR-223 binding site is identified at the 3’-UTR of IGFR1mRNA). The miR-223 KO livers also contained higher level ofphospho-Akt, a downstream molecule activated by IGFR1.These findings provide novel evidence that miR-223 deficiencyprevents Fas-induced hepatocyte apoptosis and liver failurethrough up-regulated IGFR1.
Disclosures:
The following people have nothing to disclose: Ximena V. Qadir, Chang Han,Tong Wu
The n e w e ng l a n d j o u r na l of m e dic i n e review article CRITICAL CARE MEDICINE Acute Liver Failure cute liver failure is a...
Gene Therapy for Acute Liver Failure Current Gene Therapy, 2010, Vol. 10, No. 2 157 tential therapeutic targets involved in the pathogenesis of ALF in...
Liver failure Hyper - acute liver failure Acute liver failure Greatest risk of cerebral oedema, CVS failure Greatest chance of spontaneous survival Sub - ...
If acute liver failure due to a pregnancy-related cause (such as acute fatty liver of pregnancy) is a possible differential diagnosis, urgent delivery of...
APASL Acute-on-chronic liver failure_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 APASL Acute-on-chronic liver failure_临床医学_医药卫生...
PFIC type III in infant presenting as acute liver cell failure 2010_临床医学_医药卫生_专业资料。case report PFIC type III in infant presenting as acute ...
Acute Renal Failure_基础医学_医药卫生_专业资料。Acute Renal Failure ? Definition...after restoration of hepatic function after liver transplantation Type I HRS...
哪几肝衰竭分为急性肝衰竭(acute liver failure, ALF) ,亚急性肝衰竭(subacute liver failure, SALF)和慢性肝衰竭(chronic liver failure, CLF) 。 急性肝衰竭 ...
pregnancy, AFLP)是妊娠晚期特发的严重肝脏损害又名为妊娠期 特发性脂肪肝(Idiopathic acute fatty liver of pregnancy)或妊娠期急性肝衰竭(acute liver failure) ...
急性肝衰竭的处理(AASLD 指导意见) 王宇明 晏泽辉 导言 《急性肝衰竭(acute liver failure, ALF)的处理》的推荐意见建立在一种证据分级的标准上。 作者采用了...
热门文档